<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38319477</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-2592</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Journal of clinical immunology</Title><ISOAbbreviation>J Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.</ArticleTitle><Pagination><StartPage>59</StartPage><MedlinePgn>59</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">59</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-024-01656-2</ELocationID><Abstract><AbstractText>The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection and lasting&#x2009;&gt;&#x2009;12&#xa0;weeks. In common variable immunodeficiency (CVID) patients, we previously reported higher risk of hospitalization and death during SARS-CoV-2 infection, as well as prolonged swab positivity and frequent reinfections. The aim of the present study was to assess the risk of LC in an Italian cohort of CVID patients. We used a translated version of the survey proposed by Centers for Disease Control and Prevention (CDC) to collect data on LC. In the enrolled cohort of 175 CVID patients, we found a high prevalence of LC (65.7%). The most frequent LC symptoms were fatigue (75.7%), arthralgia/myalgia (48.7%), and dyspnea (41.7%). The majority of patients (60%) experienced prolonged symptoms, for at least 6&#xa0;months after infection. In a multivariate analysis, the presence of complicated phenotype (OR 2.44, 95% CI 1.88-5.03; p&#x2009;=&#x2009;0.015), obesity (OR 11.17, 95% CI 1.37-90.95; p&#x2009;=&#x2009;0.024), and female sex (OR 2.06, 95% CI 1.09-3.89; p&#x2009;=&#x2009;0.024) significantly correlated with the development of LC. In conclusion, in this multicenter observational cohort study, we demonstrated that CVID patients present an increased prevalence of LC when compared to the general population. Improved awareness on the risk of LC in CVID patients could optimize management of this new and alarming complication of SARS-CoV-2 infection.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Villa</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Milito</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deiana</LastName><ForeName>Carla Maria</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finco Gambier</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punziano</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buso</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bez</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagnese</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannuzzi</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagnozzi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalm</LastName><ForeName>Virgil A S H</ForeName><Initials>VASH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Allergy &amp; Clinical Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spadaro</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rattazzi</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cinetto</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8486-5850</Identifier><AffiliationInfo><Affiliation>Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy. francesco.cinetto@unipd.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Firinu</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Immunol</MedlineTA><NlmUniqueID>8102137</NlmUniqueID><ISSNLinking>0271-9142</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017074" MajorTopicYN="Y">Common Variable Immunodeficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">chronic lung disease</Keyword><Keyword MajorTopicYN="N">common variable immunodeficiency</Keyword><Keyword MajorTopicYN="N">complicated phenotype</Keyword><Keyword MajorTopicYN="N">obesity</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38319477</ArticleId><ArticleId IdType="pmc">PMC10847195</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01656-2</ArticleId><ArticleId IdType="pii">10.1007/s10875-024-01656-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19) situation reports [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.&#xa0;Accessed 22 Dec 2023.</Citation></Reference><Reference><Citation>Faghy MA, Owen R, Thomas C, Yates J, Ferraro FV, Skipper L, et al. Is long COVID the next global health crisis? J Glob Health. 2022;12:03067. 10.7189/jogh.12.03067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597397</ArticleId><ArticleId IdType="pubmed">36285549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol. 2021;12. 10.3389/fimmu.2021.656797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanevik K, Wensaas K-A, Rortveit G, Eide GE, M&#xf8;rch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59:1394&#x2013;400. 10.1093/cid/ciu629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207419</ArticleId><ArticleId IdType="pubmed">25115874</ArticleId></ArticleIdList></Reference><Reference><Citation>Masood M, Chodisetti S, BaHammam A. Long COVID: the long-term consequences of COVID-19 and the proposed pathophysiological mechanisms. J Nat Sci Med. 2023;6(1):3&#x2013;11. 10.4103/jnsm.jnsm_133_22.</Citation></Reference><Reference><Citation>Post COVID-19 condition [Internet]. Available from: https://www.who.int/teams/health-care-readiness/post-covid-19-condition.&#xa0;Accessed 22 Dec 2023.</Citation></Reference><Reference><Citation>Post COVID-19 condition (long COVID) [Internet]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.&#xa0;Accessed 22 Dec 2023</Citation></Reference><Reference><Citation>Ford ND. Long COVID and significant activity limitation among adults, by age &#x2014; United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep [Internet]. 2023;72. Available from: https://www.cdc.gov/mmwr/volumes/72/wr/mm7232a3.htm.&#xa0;Accessed 22 Dec 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi HY, Alrashed AM, Jawhari AM, Abdel-Moneim AS. Neuropsychiatric symptoms in post-COVID-19 long haulers. Acta Neuropsychiatr. 2022;34:318&#x2013;29. 10.1017/neu.2022.13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35543105</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;14. 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol. 2022;94:253&#x2013;62. 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593&#x2013;607. 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Zhang J, Tang HT, Wong HK, Lyu A, Cheung CH, et al. Prevalence and risk factors of long COVID 6&#x2013;12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. J Med Virol. 2023;95: e28862. 10.1002/jmv.28862.</Citation><ArticleIdList><ArticleId IdType="pubmed">37334978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Mudara C, Vika C, Welch R, Arendse T, Dryden M, et al. A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023;128:102&#x2013;11. 10.1016/j.ijid.2022.12.036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9800016</ArticleId><ArticleId IdType="pubmed">36587841</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, Dasmari&#xf1;as MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373: n1098. 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Pellicer-Valero OJ, Navarro-Pardo E, Palacios-Ce&#xf1;a D, Florencio LL, Guijarro C, et al. Symptoms experienced at the acute phase of SARS-CoV-2 infection as risk factor of long-term post-COVID symptoms: the LONG-COVID-EXP-CM multicenter study. Int J Infect Dis. 2022;116:241&#x2013;4. 10.1016/j.ijid.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743274</ArticleId><ArticleId IdType="pubmed">35017102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristillo V, Pilotto A, Cotti Piccinelli S, Bonzi G, Canale A, Gipponi S, et al. Premorbid vulnerability and disease severity impact on long-COVID cognitive impairment. Aging Clin Exp Res. 2022;34:257&#x2013;60. 10.1007/s40520-021-02042-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8747881</ArticleId><ArticleId IdType="pubmed">35014002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:12422. 10.3390/ijerph191912422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Fern&#xe1;ndez M, Padilla S, Garc&#xed;a JA, Agull&#xf3; V, Lozano V, et al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13: 920627. 10.3389/fimmu.2022.920627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13:446. 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7:1763&#x2013;70. 10.1016/j.jaip.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">30776527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye SG, COVID Human Genetic Effort consortium. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol. 2023;151:818&#x2013;31. 10.1016/j.jaci.2022.11.010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9746792</ArticleId><ArticleId IdType="pubmed">36522221</ArticleId></ArticleIdList></Reference><Reference><Citation>Giardino G, Milito C, Lougaris V, Punziano A, Carrabba M, Cinetto F, et al. The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the Italian Primary Immunodeficiencies Network (IPINet). J Clin Immunol. 2022;42:935&#x2013;46. 10.1007/s10875-022-01264-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020753</ArticleId><ArticleId IdType="pubmed">35445287</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147:870-875.e1. 10.1016/j.jaci.2020.12.620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737531</ArticleId><ArticleId IdType="pubmed">33338534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42:1508&#x2013;20. 10.1007/s10875-022-01352-z.</Citation><ArticleIdList><ArticleId IdType="pubmed">36198931</ArticleId></ArticleIdList></Reference><Reference><Citation>Milito C, Firinu D, Bez P, Villa A, Punziano A, Lagnese G, et al. A beacon in the dark: COVID-19 course in CVID patients from two European countries: different approaches, similar outcomes. Front Immunol. 2023;14:1093385. 10.3389/fimmu.2023.1093385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9944020</ArticleId><ArticleId IdType="pubmed">36845159</ArticleId></ArticleIdList></Reference><Reference><Citation>Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Allergy Clin Immunol Pract. 2021;9:2904-2906.e2. 10.1016/j.jaip.2021.04.017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8059325</ArticleId><ArticleId IdType="pubmed">33894392</ArticleId></ArticleIdList></Reference><Reference><Citation>ESID - European Society for Immunodeficiencies [Internet]. Available from: https://esid.org/Working-Parties/Registry-Working-Party/.&#xa0;Accessed 22 Dec 2023</Citation></Reference><Reference><Citation>Sanit&#xe0; E-IS di. EpiCentro [Internet]. Available from: https://www.epicentro.iss.it/.&#xa0;Accessed 22 Dec 2023</Citation></Reference><Reference><Citation>Bergna A, Lai A, Ventura CD, et al. Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy in 2020 and 2022 period. Authorea Preprints; 2023. 10.22541/au.168931270.03874429/v1.</Citation></Reference><Reference><Citation>Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol. 2012;130:1197-1198.e9. 10.1016/j.jaci.2012.05.046.</Citation><ArticleIdList><ArticleId IdType="pubmed">22819511</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192&#x2013;7. 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;7. 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID - household pulse survey - COVID-19 [Internet]. Available from: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.&#xa0;Accessed 22 Dec 2023</Citation></Reference><Reference><Citation>Yazdani R, Habibi S, Sharifi L, Azizi G, Abolhassani H, Olbrich P, et al. Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management. J Investig Allergol Clin Immunol. 2020;30:14&#x2013;34. 10.18176/jiaci.0388.</Citation><ArticleIdList><ArticleId IdType="pubmed">30741636</ArticleId></ArticleIdList></Reference><Reference><Citation>Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-571.e1. 10.1016/j.anai.2022.06.009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212748</ArticleId><ArticleId IdType="pubmed">35718282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J. 2023;20:124. 10.1186/s12985-023-02061-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10276420</ArticleId><ArticleId IdType="pubmed">37328773</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;6. 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar J, Guffey D, Minard CG, Orange JS. Increased incidence of fatigue in patients with primary immunodeficiency disorders: prevalence and associations within the US Immunodeficiency Network Registry. J Clin Immunol. 2017;37:153&#x2013;65. 10.1007/s10875-016-0367-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5326589</ArticleId><ArticleId IdType="pubmed">28124237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JY, Liu MY, Hung KC, Hsu WH, Tsai YW, Liu TH, et al. Nutritional deficiency anemia and post-acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: a six-month retrospective cohort analysis of 30 892 patients. J Med Virol. 2023;95(11): e29246. 10.1002/jmv.29246.</Citation><ArticleIdList><ArticleId IdType="pubmed">38010833</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lollo C, de MoraesVasconcelos D, da Silva Oliveira LM, Domingues R, de Carvalho GC, da Silva Duarte AJ, et al. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency. Clin Immunol Orlando Fla. 2016;169:121&#x2013;7. 10.1016/j.clim.2016.07.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">27392462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12: 645013. 10.3389/fimmu.2021.645013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon L, Perez-Sancristobal I, Madrid A, Lopez-Pedraza L, Colomer JI, Lerma S, et al. Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. Rheumatol Adv Pract. 2022;6:rkac008. 10.1093/rap/rkac008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882379</ArticleId><ArticleId IdType="pubmed">35233480</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R, et al. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. Lancet Rheumatol. 2023;5:e375&#x2013;85. 10.1016/S2665-9913(23)00127-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292827</ArticleId><ArticleId IdType="pubmed">37398978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SH, Kim JL, Kim JR, Lee SH, Yim HW, Jeong H, et al. Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period. J Psychiatr Res. 2021;137:1&#x2013;6. 10.1016/j.jpsychires.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888998</ArticleId><ArticleId IdType="pubmed">33631632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivalta B, Amodio D, Milito C, Chiriaco M, Di Cesare S, Giancotta C, et al. Case report: ebv chronic infection and lymphoproliferation in four APDS patients: the challenge of proper characterization, therapy, and follow-up. Front Pediatr. 2021;27(9): 703853. 10.3389/fped.2021.703853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448282</ArticleId><ArticleId IdType="pubmed">34540765</ArticleId></ArticleIdList></Reference><Reference><Citation>Allain V, Grandin V, Meignin V, Bertinchamp R, Boutboul D, Fieschi C, Galicier L, et al. Lymphoma as an exclusion criteria for CVID diagnosis revisited. J Clin Immunol. 2023;43(1):181&#x2013;91. 10.1007/s10875-022-01368-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">36155879</ArticleId></ArticleIdList></Reference><Reference><Citation>von Spee-Mayer C, Echternach C, Agarwal P, Gutenberger S, Soetedjo V, Goldacker S, et al. Abatacept use is associated with steroid dose reduction and improvement in fatigue and CD4-dysregulation in CVID patients with interstitial lung disease. J Allergy Clin Immunol Pract. 2021;9:760-770.e10. 10.1016/j.jaip.2020.10.028.</Citation><ArticleIdList><ArticleId IdType="pubmed">33223097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, et al. Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8(6):1894-1899.e2. 10.1016/j.jaip.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195351</ArticleId><ArticleId IdType="pubmed">32278865</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64:66&#x2013;74. 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugazzaro S, Contri A, Esseroukh O, Kaleci S, Croci S, Massari M, et al. Rehabilitation interventions for post-acute COVID-19 syndrome: a systematic review. Int J Environ Res Public Health. 2022;19:5185. 10.3390/ijerph19095185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9104923</ArticleId><ArticleId IdType="pubmed">35564579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>